☰

Samuel Rabkin - Publications

Affiliations: 
Harvard Medical School, Boston, MA, United States 
Area:
HSV Vectors for Cancer Therapy
Tree Info Grants Similar researchers PubMed Report error

67 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Shimizu K, Kahramanian A, Jabbar MADA, Turna Demir F, Gokyer D, Uthamacumaran A, Rajan A, Saad MA, Gorham J, Wakimoto H, Martuza RL, Rabkin SD, Hasan T, Wakimoto H. Photodynamic augmentation of oncolytic virus therapy for central nervous system malignancies. Cancer Letters. 572: 216363. PMID 37619813 DOI: 10.1016/j.canlet.2023.216363  0.339
2023 Kardani K, Sanchez Gil J, Rabkin SD. Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells. Frontiers in Cellular and Infection Microbiology. 13: 1206111. PMID 37325516 DOI: 10.3389/fcimb.2023.1206111  0.376
2022 Kawamura Y, Hua L, Gurtner A, Wong E, Kiyokawa J, Shah N, Gorham J, Wakimoto H, Rabkin SD, Martuza RL, Wakimoto H. Histone deacetylase inhibitors enhance oncolytic herpes simplex virus therapy for malignant meningioma. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 155: 113843. PMID 36271587 DOI: 10.1016/j.biopha.2022.113843  0.332
2021 Jahan N, Ghouse SM, Martuza RL, Rabkin SD. In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV. Viruses. 13. PMID 34578321 DOI: 10.3390/v13091740  0.326
2021 Nguyen HM, Sah N, Humphrey MRM, Rabkin SD, Saha D. Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus. Journal of Visualized Experiments : Jove. PMID 34057449 DOI: 10.3791/62677  0.32
2020 Li M, Li G, Kiyokawa J, Tirmizi Z, Richardson LG, Ning J, Das S, Martuza RL, Stemmer-Rachamimov A, Rabkin SD, Wakimoto H. Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. Acta Neuropathologica Communications. 8: 221. PMID 33308315 DOI: 10.1186/s40478-020-01096-0  0.351
2019 Bommareddy PK, Lowe DB, Kaufman HL, Rabkin SD, Saha D. Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma. Journal of Biological Methods. 6. PMID 31123687  0.301
2019 Wang L, Ning J, Wakimoto H, Wu S, Wu CL, Humphrey MR, Rabkin SD, Martuza RL. Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells. Molecular Therapy Oncolytics. 13: 58-66. PMID 31016228 DOI: 10.1016/j.omto.2019.03.008  0.32
2018 Bommareddy PK, Aspromonte S, Zloza A, Rabkin SD, Kaufman HL. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. Science Translational Medicine. 10. PMID 30541787 DOI: 10.1126/Scitranslmed.Aau0417  0.345
2018 Saha D, Martuza RL, Rabkin SD. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma. Immunotherapy. 10: 779-786. PMID 30008259 DOI: 10.2217/imt-2018-0009  0.352
2018 Peters C, Paget M, Tshilenge KT, Saha D, Antoszczyk S, Baars A, Frost T, Martuza RL, Wakimoto H, Rabkin SD. RESTRICTION OF γ34.5-DELETED ONCOLYTIC HERPES SIMPLEX VIRUS REPLICATION IN GLIOBLASTOMA STEM-LIKE CELLS. Journal of Virology. PMID 29793956 DOI: 10.1128/JVI.00246-18  0.387
2018 Hua L, Gartner A, Kiyokawa J, Rabkin S, Martuza R, Wakimoto H. EXTH-20. HISTONE DEACETYLASE INHIBITOR ENHANCES ONCOLYTIC HERPES SIMPLEX VIRUS THERAPY FOR MALIGNANT MENINGIOMA Neuro-Oncology. 20: vi89-vi89. DOI: 10.1093/Neuonc/Noy148.369  0.36
2017 Esaki S, Nigim F, Moon E, Luk S, Kiyokawa J, Curry W, Cahill DP, Chi AS, Iafrate AJ, Martuza RL, Rabkin SD, Wakimoto H. Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models. International Journal of Cancer. PMID 28801914 DOI: 10.1002/ijc.30929  0.302
2016 Saha D, Wakimoto H, Rabkin SD. Oncolytic herpes simplex virus interactions with the host immune system. Current Opinion in Virology. 21: 26-34. PMID 27497296 DOI: 10.1016/j.coviro.2016.07.007  0.307
2016 Esaki S, Rabkin SD, Martuza RL, Wakimoto H. Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma. American Journal of Cancer Research. 6: 300-11. PMID 27186404  0.335
2016 Saha D, Martuza R, Rabkin S. Abstract B116: Immunovirotherapy in combination with immune checkpoint inhibitors for treating glioblastoma Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B116  0.431
2015 Saha D, Ahmed SS, Rabkin SD. EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA. Drugs of the Future. 40: 739-749. PMID 26855472 DOI: 10.1358/dof.2015.040.11.2383070  0.379
2015 Ning J, Wakimoto H, Martuza R, Rabkin S. Abstract 4227: PARP inhibitors sensitize glioblastoma stem cells to oncolytic herpes simplex virus therapy Cancer Research. 75: 4227-4227. DOI: 10.1158/1538-7445.Am2015-4227  0.436
2015 VanderVeen NT, Raja N, Yi E, Curtin J, Chockley P, Assi H, Savakus J, Mikkelsen T, Rabkin S, Lowenstein PR, Castro MG. Abstract 3195: STAT3 inhibition using shRNA inhibits GBM proliferation, cell migration, anchorage-independent growth of mouse, rat, and human stem-like cells in vitro; and it induces long term survival and anti-GBM immunity in vivo Cancer Research. 75: 3195-3195. DOI: 10.1158/1538-7445.Am2015-3195  0.411
2014 Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunology Research. 2: 295-300. PMID 24764576 DOI: 10.1158/2326-6066.CIR-14-0015  0.327
2014 Antoszczyk S, Spyra M, Mautner VF, Kurtz A, Stemmer-Rachamimov AO, Martuza RL, Rabkin SD. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus. Neuro-Oncology. 16: 1057-66. PMID 24470552 DOI: 10.1093/Neuonc/Not317  0.319
2013 Cheema TA, Wakimoto H, Fecci PE, Ning J, Kuroda T, Jeyaretna DS, Martuza RL, Rabkin SD. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proceedings of the National Academy of Sciences of the United States of America. 110: 12006-11. PMID 23754388 DOI: 10.1073/pnas.1307935110  0.406
2013 Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, Jeyaretna DS, Stemmer Rachamimov AO, Rabkin SD, Martuza RL. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia (New York, N.Y.). 15: 591-9. PMID 23730207 DOI: 10.1593/Neo.13158  0.35
2013 Kanai R, Rabkin SD. Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors. Cns Oncology. 2: 129-42. PMID 23687568 DOI: 10.2217/cns.12.42  0.366
2013 Murphy AM, Rabkin SD. Current status of gene therapy for brain tumors. Translational Research : the Journal of Laboratory and Clinical Medicine. 161: 339-54. PMID 23246627 DOI: 10.1016/J.Trsl.2012.11.003  0.366
2013 Passer BJ, Cheema T, Wu S, Wu CL, Rabkin SD, Martuza RL. Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models. Cancer Gene Therapy. 20: 17-24. PMID 23138870 DOI: 10.1038/cgt.2012.75  0.319
2013 Tamura K, Wakimoto H, Agarwal AS, Rabkin SD, Bhere D, Martuza RL, Kuroda T, Kasmieh R, Shah K. Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 68-77. PMID 22929661 DOI: 10.1038/Mt.2012.175  0.317
2012 Sgubin D, Wakimoto H, Kanai R, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells. Stem Cells Translational Medicine. 1: 322-32. PMID 23197811 DOI: 10.5966/sctm.2011-0035  0.355
2012 Barnard Z, Wakimoto H, Zaupa C, Patel AP, Klehm J, Martuza RL, Rabkin SD, Curry WT. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma. Neurosurgery. 71: 741-8; discussion 74. PMID 22653387 DOI: 10.1227/NEU.0b013e318260fd73  0.309
2012 Kanai R, Zaupa C, Sgubin D, Antoszczyk SJ, Martuza RL, Wakimoto H, Rabkin SD. Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. Journal of Virology. 86: 4420-31. PMID 22345479 DOI: 10.1128/JVI.00017-12  0.374
2012 Kanai R, Rabkin SD, Yip S, Sgubin D, Zaupa CM, Hirose Y, Louis DN, Wakimoto H, Martuza RL. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. Journal of the National Cancer Institute. 104: 42-55. PMID 22173583 DOI: 10.1093/Jnci/Djr509  0.338
2012 Zhang W, Fulci G, Buhrman JS, Stemmer-Rachamimov AO, Chen JW, Wojtkiewicz GR, Weissleder R, Rabkin SD, Martuza RL. Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 37-45. PMID 21915104 DOI: 10.1038/Mt.2011.187  0.337
2011 Cheema TA, Kanai R, Kim GW, Wakimoto H, Passer B, Rabkin SD, Martuza RL. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7383-93. PMID 21976549 DOI: 10.1158/1078-0432.CCR-11-1762  0.339
2011 Kleijn A, Chen JW, Buhrman JS, Wojtkiewicz GR, Iwamoto Y, Lamfers ML, Stemmer-Rachamimov AO, Rabkin SD, Weissleder R, Martuza RL, Fulci G. Distinguishing inflammation from tumor and peritumoral edema by myeloperoxidase magnetic resonance imaging. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4484-93. PMID 21558403 DOI: 10.1158/1078-0432.Ccr-11-0575  0.329
2011 Kanai R, Wakimoto H, Martuza RL, Rabkin SD. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3686-96. PMID 21505062 DOI: 10.1158/1078-0432.CCR-10-3142  0.322
2011 Cheema TA, Wakimoto H, Rabkin S, Martuza RL. Abstract 5389: Oncolytic herpes simplex virus expressing interleukin-12 for treating glioma stem cells Cancer Research. 71: 5389-5389. DOI: 10.1158/1538-7445.Am2011-5389  0.426
2010 Passer BJ, Cheema T, Zhou B, Wakimoto H, Zaupa C, Razmjoo M, Sarte J, Wu S, Wu CL, Noah JW, Li Q, Buolamwini JK, Yen Y, Rabkin SD, Martuza RL. Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Research. 70: 3890-5. PMID 20424118 DOI: 10.1158/0008-5472.Can-10-0155  0.327
2010 Maguire CA, Gianni D, Meijer DH, Shaket LA, Wakimoto H, Rabkin SD, Gao G, Sena-Esteves M. Directed evolution of adeno-associated virus for glioma cell transduction. Journal of Neuro-Oncology. 96: 337-47. PMID 19618115 DOI: 10.1007/S11060-009-9972-7  0.349
2010 Liu R, Wang J, Rabkin S. Abstract P2-18-01: Treatment of Human Breast Tumors by Oncolytic Herpes Simplex Virus Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P2-18-01  0.371
2009 Wakimoto H, Kesari S, Farrell CJ, Curry WT, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, Jeyaretna DS, Debasitis J, Pruszak J, Martuza RL, Rabkin SD. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Research. 69: 3472-81. PMID 19351838 DOI: 10.1158/0008-5472.Can-08-3886  0.376
2009 Passer BJ, Castelo-Branco P, Buhrman JS, Varghese S, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells. Cancer Gene Therapy. 16: 551-60. PMID 19197321 DOI: 10.1038/Cgt.2009.10  0.326
2009 Aghi MK, Liu TC, Rabkin S, Martuza RL. Hypoxia enhances the replication of oncolytic herpes simplex virus. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 51-6. PMID 18957963 DOI: 10.1038/Mt.2008.232  0.453
2008 Farrell CJ, Zaupa C, Barnard Z, Maley J, Martuza RL, Rabkin SD, Curry WT. Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7711-6. PMID 19047097 DOI: 10.1158/1078-0432.CCR-08-1364  0.353
2008 Liu TC, Castelo-Branco P, Rabkin SD, Martuza RL. Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1041-7. PMID 18388912 DOI: 10.1038/mt.2008.58  0.334
2008 Aghi MK, Liu TC, Rabkin S, Martuza RL. Glioblastoma Hypoxia Promotes Oncolytic HSV Replication in vitro and in vivo Neurosurgery. 62: 1423-1424. DOI: 10.1227/01.Neu.0000333526.39409.10  0.374
2007 Varghese S, Rabkin SD, Nielsen GP, MacGarvey U, Liu R, Martuza RL. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Research. 67: 9371-9. PMID 17909046 DOI: 10.1158/0008-5472.CAN-07-0674  0.315
2007 Liu TC, Wakimoto H, Martuza RL, Rabkin SD. Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5897-902. PMID 17908985 DOI: 10.1158/1078-0432.CCR-07-1013  0.374
2007 Jeyaretna DS, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus therapy for peripheral nerve tumors. Neurosurgical Focus. 22: E4. PMID 17613221 DOI: 10.3171/Foc.2007.22.6.5  0.352
2007 Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, Liu TC, Rabkin S, Martuza R, Breakefield XO. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Cancer Gene Therapy. 14: 460-7. PMID 17304235 DOI: 10.1038/Sj.Cgt.7701037  0.442
2007 Aghi M, Rabkin SD, Martuza RL. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Research. 67: 440-4. PMID 17234749 DOI: 10.1158/0008-5472.CAN-06-3145  0.349
2006 Aghi M, Rabkin S, Martuza RL. Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair. Clinical Neurosurgery. 53: 65-76. PMID 17380741  0.31
2006 Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X, Bikfalvi A, Martuza RL, Kurtz A, Rabkin SD. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6791-9. PMID 17121900 DOI: 10.1158/1078-0432.CCR-06-0263  0.374
2006 Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Martuza RL, Rabkin SD, Kurtz A. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 14: 789-97. PMID 17045531 DOI: 10.1016/j.ymthe.2006.07.011  0.376
2006 Kuroda T, Martuza RL, Todo T, Rabkin SD. Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases. Bmc Biotechnology. 6: 40. PMID 16995942 DOI: 10.1186/1472-6750-6-40  0.326
2006 Varghese S, Rabkin SD, Nielsen PG, Wang W, Martuza RL. Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2919-27. PMID 16675589 DOI: 10.1158/1078-0432.CCR-05-1187  0.301
2006 Messerli SM, Prabhakar S, Tang Y, Mahmood U, Giovannini M, Weissleder R, Bronson R, Martuza R, Rabkin S, Breakefield XO. Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Human Gene Therapy. 17: 20-30. PMID 16409122 DOI: 10.1089/Hum.2006.17.20  0.435
2006 Aghi M, Rabkin S, Martuza RL. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. Journal of the National Cancer Institute. 98: 38-50. PMID 16391370 DOI: 10.1093/Jnci/Djj003  0.418
2006 Aghi M, Rabkin S. Viral vectors as therapeutic agents for glioblastoma. Current Opinion in Molecular Therapeutics. 7: 419-30. PMID 16248277  0.356
2006 Messerli S, Prabhakar S, Tang Y, Mahmood U, Giovannini M, Weissleder R, Bronson R, Martuza R, Rabkin S, Breakefield XO. Erratum: Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2 (Human Gene Therapy (January 2006) 17, 1 (20-30)) Human Gene Therapy. 17. DOI: 10.1089/Hum.2006.17.796  0.377
2006 Prabhakar S, Messerli S, Rabkin S, Martuza R, Breakefield XO. 151. Treatment of Experimental Schwannomas with HSV Recombinant and Amplicon Vectors Molecular Therapy. 13: S59. DOI: 10.1016/J.Ymthe.2006.08.174  0.436
2005 Aghi MK, Rabkin S, Martuza RL. 840 Enhanced Replication of Oncolytic Herpes Simplex Virus in Glioma Cells that Evade Temozolomide Chemotherapy through DNA Repair. Neurosurgery. 57: 408-409. PMID 28184805 DOI: 10.1093/Neurosurgery/57.2.408B  0.414
2005 Fukuhara H, Martuza RL, Rabkin SD, Ito Y, Todo T. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 7886-90. PMID 16278413 DOI: 10.1158/1078-0432.CCR-05-1090  0.353
2005 Liu R, Varghese S, Rabkin SD. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. Cancer Research. 65: 1532-40. PMID 15735042 DOI: 10.1158/0008-5472.CAN-04-3353  0.368
2002 Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Therapy. 9: 967-78. PMID 12522436 DOI: 10.1038/sj.cgt.7700537  0.376
2001 Toda M, Martuza RL, Rabkin SD. Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine. Gene Therapy. 8: 332-9. PMID 11313808 DOI: 10.1038/Sj.Gt.3301392  0.417
1979 Becker Y, Gutter B, Cohen Y, Chejanovsky N, Rabkin S, Fridlender B. Herpes simplex virus DNA polymerase, thymidine kinase and deoxyribonuclease activities in cells infected with wild type, ultraviolet-irradiated and defective virus. Archives of Virology. 62: 163-174. PMID 229801 DOI: 10.1007/Bf01317549  0.385
1978 Becker Y, Asher Y, Weinberg-Zahlering E, Rabkin S, Friedmann A, Kessler E. Defective herpes simplex virus DNA: circular and circular-linear molecules resembling rolling circles. Journal of General Virology. 40: 319-335. PMID 211183 DOI: 10.1099/0022-1317-40-2-319  0.325
Show low-probability matches.